Charles la Porte, claporte@ohri.ca Tel: 613-737-8899 ext. 71893 Fax: 613-737-8696 General Campus (see Contact page for maps)

Associate Scientist, Chronic Disease, Ottawa Hospital Research Institute

Assistant Professor, Faculty of Medicine, University of Ottawa

Clinical Director, Clinical Investigation Unit, Division of Infectious Diseases

Dr Charles la Porte is an Associate Scientist in the Chronic Disease Program at the Ottawa Hospital Research Institute, Canada. He is the director of the Pharmacokinetic Laboratory and Clinical Investigation Unit, a 12 bed clinical facility located at the Ottawa Hospital General Campus. Furthermore he holds an appointment as assistant Professor at the University of Ottawa, Faculty of Medicine.

Charles la Porte obtained his PharmD at Utrecht University in The Netherlands. After completing his PharmD he started in his PhD, which he completed in 2005 at Radboud University in Nijmegen in The Netherlands. During his PhD he did research on clinical pharmacology of antiretroviral agents, with a focus on drug interactions and dose modifications.

Charles la Porte’s research program is focused on pharmacology of antiretroviral drugs. Research projects include drug interaction and bioequivalence studies as well as studies that explore the mechanistic background, including pharmacogenetics, of the pharmacokinetic observations. These studies are performed in healthy volunteers or HIV patients, depending on the study design. He participates in research groups that receive funding from different sources such as the Ontario HIV treatment Network, Canadian Institutes of Health Research, as well as the CIHR Canadian HIV Trials Network.

He presents his work at international conferences and meetings and teaches at a yearly course in HIV Pharmacology at the University of Turin, Italy. Recent examples of his scientific publications of over 25 articles include results from studies with adult and pediatric HIV patients as well as healthy volunteers.

Selected Publications:

1. C.J.L. la Porte. Saquinavir, the pioneer antiretroviral protease inhibitor. Expert Opinion on Drug Metabolism and Toxicology. 2009 Oct;5(10):1313-22
2. C.J.L. la Porte, J.P. Sabo, L. Béïque, D.W. Cameron. Lack of effect of efavirenz on the pharmacokinetics of tipranavir/ritonavir (TPV/r) in healthy volunteers. Antimicrobial Agents and Chemotherapy. 2009 Aug 31. [Epub ahead of print]
3. P.M. Sheth, C. Kovacs, K.S. Kemal, R.B. Jones, J.M. Raboud, R. Pilon, C.J.L. la Porte, M. Ostrowski, M. Loutfy, H. Burger, B. Weiser, R. Kaul; the Toronto Mucosal Immunology Group. Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS. 2009 Sep 24;23(15):2050-4.
4. P.A. Pham, C.J.L. la Porte, L.S. Lee, R. van Heeswijk, J.P. Sabo, M.M. Elgadi, P.J. Piliero, P. Barditch-Crovo, E. Fuchs, C. Flexner, D.W. Cameron. Differential Effects of Tipranavir plus Ritonavir on Atorvastatin or Rosuvastatin Pharmacokinetics in Healthy Volunteers. Antimicrobial Agents and Chemotherapy. 2009 Oct;53(10):4385-92.
5. C.J.L. la Porte, R. van Heeswijk, C.D. Mitchell, G. Zhang, J. Parker, C. Rongkavilit. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children. Antiviral Therapy. 2009;14(4):603-6
6. G. Lorello, C.J.L. la Porte, R. Pilon, G. Zhang, Karnauchow T, P. MacPherson. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma. HIV Medicine. 2009 Oct;10(9):548-54.
7. P. Giguère, C.J.L. la Porte, G. Zhang, D.W. Cameron. Pharmacokinetics of Darunavir, Etravirine and Raltegravir in a HIV-Infected Patient on Haemodialysis. AIDS. 2009 23(6):740-2
8. C.J.L. la Porte, J.P. Sabo, M. Elgadi, D.W. Cameron. Interaction studies of tipranavir/ritonavir (TPV/r) with clarithromycin, fluconazole and rifabutin in healthy volunteers. Antimicrobial Agents and Chemotherapy. 2009. 53(1):162-73
9. C.J.L. la Porte. Inhibitory quotient in HIV pharmacology. Current opinion in HIV and AIDS. 2008. 3: 283-287.
10. L. Béïque, P. Giguère, C.J.L. la Porte, J. Angel. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Medicine. 2007. 8:335-345
11. C.J.L. la Porte, Y. Li, L. Béïque, B.C. Foster, B. Chauhan, G.E. Garber, D.W. Cameron, R.P.G. van Heeswijk. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clinical Pharmacology and Therapeutics. 2007. 82(4):389-95
12. D.M. Burger, G. Verweel, N. Rakhmanina, C.P. Verwey-van Wissen, C.J.L. la Porte, A.S. Bergshoeff, H. Lyall, N.G. Hartwig, H. Green, S. Soldin, D.M. Gibb, R. de Groot. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clinical Pharmacology and Therapeutics. 2007. 81(4):517-520
13. C.J.L. la Porte, D.J. Back, T. Blaschke, C.A.B Boucher, C.V. Fletcher, C. Flexner, J.G. Gerber, A.D.M. Kashuba, J. Schapiro, D.M. Burger. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Reviews in Antiviral Therapy. 2006. 3: 4-14
14. M.R. van der Leur, D.M. Burger, C.J.L. la Porte, P.P. Koopmans. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Therapeutic Drug Monitoring. 2006. 28(5):650-653
15. C.J.L. la Porte, J.A. Droste, D.M. Burger. False-positive results in urine drug screening in healthy volunteers participating in phase 1 studies with efavirenz and rifampin. Therapeutic Drug Monitoring. 2006. 28(2):286
16. D. Burger, I. van der Heiden, C.J.L. la Porte, M. van der Ende, P. Groeneveld, C. Richter, P. Koopmans, F. Kroon, H. Sprenger, J. Lindemans, P. Schenk and R. van Schaik. Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and genetics. British Journal of Clinical Pharmacology. 2006. 61:2;148-154